There are no products listed under this category.
STARD13
STARD13 (StAR related lipid transfer domain containing 13, also known as GT650, DLC2, ARHGAP37 and LINC00464) is a GTPase-activating protein for RhoA, and perhaps for Cdc42. It is linked to cytoskeletal regulation and acts as a tumour suppressor in hepatocellular carcinoma cells. Browse Assay Genie's current range of STARD13 research reagents below, or read on for the biology behind the target.
STARD13 is a GTPase-activating protein (GAP) for RhoA, and perhaps for Cdc42. GAPs accelerate GTP hydrolysis by small GTPases, switching them to the inactive state. Through this activity STARD13 may be involved in regulating cytoskeletal reorganisation, cell proliferation and cell motility. In hepatocellular carcinoma cells it acts as a tumour suppressor, which makes it a frequent subject in cancer biology studies.
The STARD13 protein has a modular layout. An N-terminal sterile alpha motif (SAM) supports protein-protein interactions, followed by an ATP/GTP-binding motif, the GAP domain and a C-terminal STAR-related lipid transfer (START) domain. UniProt reports the protein in the cytoplasm, at membranes including the mitochondrial membrane, and on lipid droplets. The STARD13 gene also produces alternatively spliced transcript variants that encode different isoforms. The mouse ortholog is Stard13.
HGNC places STARD13 in two groups: Rho GTPase activating proteins and StAR related lipid transfer domain containing proteins. Previous names include START domain containing 13 and long intergenic non-protein coding RNA 464, and DLC2 and ARHGAP37 remain in use as aliases. The gene lies in a region of chromosome 13 associated with loss of heterozygosity in hepatocellular carcinomas, in keeping with its reported tumour-suppressor role in hepatoma cells.
STARD13 acts as a tumour suppressor in hepatoma cells, and its genomic region shows loss of heterozygosity in hepatocellular carcinomas.
As a GTPase-activating protein for RhoA, and perhaps Cdc42, STARD13 is a tool for studying how Rho family activity is controlled.
STARD13 may be involved in regulating cytoskeletal reorganisation, making it relevant to studies of cell shape and structure.
STARD13 may regulate cell proliferation and cell motility, two processes often examined in tumour suppressor and cancer cell biology.
STARD13 is a GTPase-activating protein for RhoA, and perhaps for Cdc42. It may be involved in regulating cytoskeletal reorganisation, cell proliferation and cell motility, and it acts as a tumour suppressor in hepatocellular carcinoma cells.
STARD13 is also known as GT650, DLC2, ARHGAP37 and LINC00464. Earlier names were START domain containing 13 and long intergenic non-protein coding RNA 464. Alternative splicing of the gene gives transcript variants that encode different isoforms.
The STARD13 gene lies in a region of chromosome 13 with loss of heterozygosity in hepatocellular carcinomas, and the protein acts as a tumour suppressor in hepatoma cells. A mouse ortholog, Stard13, exists; check the datasheet of any product for its validated reactivity.
Other StAR-related lipid transfer domain proteins with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9Y3M8; product specifications from Assay Genie datasheets.
There are no products listed under this category.